ST. JOSEPH, Mich., Jan. 30 /PRNewswire/ -- GeneGo, Inc., a leading provider of software and databases for systems biology, today announced that St. Jude Children's Research Hospital has licensed its data mining suite MetaCore. The latest version MetaCore 4.2 includes a novel GeneGo ontology of cellular process networks, which goes a step beyond GO ontology which is also available in MetaCore. It contains additional functional processes and more genes have been networked using GeneGo proprietary network algorithms. MetaCore has an in depth knowledge base for pediatric cancer and the unique ability to concurrently visualize gene expression and proteomics data. MetaCore also covers many species including human, mouse, rat, chicken, dog, worm, yeast and chimpanzee. MetaCore spans research, discovery and clinical trials.
About GeneGo
GeneGo develops systems biology technology for life science research. The original computational platform allows an integration and expert analysis of different kinds of experimental data (mRNA expression, proteomics, metabolomics, microRNA assays and other phenotypic data) and relevant bioactive chemistry (metabolites, drugs, other xenobiotics) within the framework of curated biological pathways and networks. GeneGo's flagship product, MetaCore 4.2, assists pharmaceutical scientists in the areas of target selection and validation, identification of biomarkers for disease states and toxicology. The second product, MetaDrug(TM) is designed for prediction of human metabolism, toxicity and biological effects for novel small molecules compounds. MetaBase(TM) represents the knowledge base for MetaCore. For more information, please visit the company's web site at www.genego.com
MetaCore(TM), MetaBase(TM) and MetaDrug(TM) are trademarks of GeneGo, Inc
GeneGo, Inc.CONTACT: Julie Bryant, VP Business Development and Marketing of GeneGo,Inc., +1-858-756-7996, julie@genego.com
Web site: http://www.genego.com/
